2seventy bio Inc. (TSVT) News
Filter TSVT News Items
TSVT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TSVT News Highlights
- For TSVT, its 30 day story count is now at 3.
- Over the past 6 days, the trend for TSVT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- BIO and ASH are the most mentioned tickers in articles about TSVT.
Latest TSVT News From Around the Web
Below are the latest news stories about 2SEVENTY BIO INC that investors may wish to consider to help them evaluate TSVT as an investment opportunity.
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3PRINCETON, N.J., & CAMBRIDGE, Mass., December 12, 2023--Abecma Delivers Sustained Progression-Free Survival Vs. Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma.... |
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)CAMBRIDGE, Mass., December 11, 2023--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that the Company will host a conference call on Tuesday, December 12, 2023, at 8:00am ET. The event will highlight data presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from December 9-12, 2023, in San Diego. |
2seventy bio Reiterates Commitment to Maximizing Shareholder ValueCAMBRIDGE, Mass., December 06, 2023--2seventy bio, Inc. (NASDAQ: TSVT), ("2seventy" or "the Company"), a leading immuno-oncology cell therapy company, today issued the following statement reiterating its commitment to maximizing shareholder value: |
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple MyelomaPRINCETON, N.J. & CAMBRIDGE, Mass., November 20, 2023--BMS and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel).... |
3 Biotech Stocks With Key Catalysts Coming in DecemberSome of the most exciting opportunities can be found in biotech stocks, especially if there's a powerful catalyst just around the corner. |
2seventy bio Reports Third Quarter Financial Results and Recent Operational ProgressCAMBRIDGE, Mass., November 14, 2023--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the third quarter ended September 30, 2023. |
2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023CAMBRIDGE, Mass., November 10, 2023--2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its third quarter 2023 financial results on Tuesday, November 14, 2023. 2seventy bio will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide a business update. |
2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial RunwayCAMBRIDGE, Mass., September 12, 2023--2seventy bio, Inc. (Nasdaq: TSVT), today announced a restructuring of its business operations and research and development model to significantly reduce costs while supporting the execution of a prioritized plan for the long-term growth of the company. |
2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune TherapiesCAMBRIDGE, Mass. & SHANGHAI, China, September 12, 2023--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, and JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, today announced their intention to expand their strategic alliance. The expansion, based on the partnership that was established last year, builds upon the companies’ translational and cli |
2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare ConferenceCAMBRIDGE, Mass., September 06, 2023--2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will participate in a fireside chat at the upcoming 2023 Morgan Stanley Global Healthcare Conference on September 13, 2023 at 3:35pm ET in New York. |